Special Issue

Roles of T Cells in Immunotherapy

Message from the Guest Editors

Tumor immunotherapies have achieved important success, but they still have some problems, such as low effective rate and unclear effectiveness. As important effector cells of human immunity, T cells are directly or indirectly involved in tumor immunotherapies. Therefore, in-depth analysis of the roles of T cells in different immunotherapies is an effective way to improve their clinical efficacy. In this Special Issue, we welcome the submission of original research papers and reviews on the roles of T cells in immunotherapy. Relevant topics of interest to this Special Issue include (but are not limited to):

- Recognition of T-cell epitopes or tumor neoantigens;
- Design of tumor vaccines;
- T-cell antigen recognition;
- Design of TCR-based immunotherapies;
- Regulation of T-cell activities.

Guest Editors

Dr. Zhan Zhou

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China

Dr. Wenbin Zhao

Zhejiang University Innovation Institute for Artificial Intelligence in Medicine, Hangzhou 310018, China

Deadline for manuscript submissions

closed (30 June 2024)

Biomedicines

**an Open Access Journal
by MDPI**

**Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed**

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).